CD8A and neoplasm: These findings demonstrated that the ability of TAMs to sustain tumor progression was partially due to their capacity to promote de-activation of CD8+ T cells, and TAM-targeted therapies induced the infiltration and activation of cytotoxic CD8+ T cells.